Multiple Myeloma Vaccine
Idiotype-specific immunotherapy in multiple myeloma is focus of review
Published in Vaccine Weekly, September 6th, 2006
According to the review from Norway, "Multiple myeloma (MM) remains a difficult-to-cure cancer and less than 20% of patients achieve long-term survival irrespective of the treatment delivered, including high-dose chemotherapy. Thus, new treatment modalities are urgently needed."
Bjarne Bogen and colleagues at the University of Oslo wrote, "Myeloma cells produce a monoclonal immunoglobulin (Ig), which is a truly tumor-specific antigen. The tumor-specific antigenic determinants are localized in the variable regions of the monoclonal Ig and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-09-06)
More Articles from Vaccine Weekly
- Leishmaniasis Vaccine
Leishmania antigens plus lipid A analogue prevent Leishmania amazonensis infection - Measles Vaccine
Maternal antibody inhibits response to measles vaccination at birth - Pneumococcal Vaccine
Intranasal vaccine protects against pneumococcal otitis media - Pneumococcal Vaccine
Prior vaccination speeds recovery time of adults with pneumococcal pneumonia - Vaccine Adjuvant
GM1 binding-deficient exotoxin is potent intradermal immunoadjuvant - Allergy & Immunology
Influence of mucosal adjuvants on antigen passage during response to airborne allergen was examined - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
